By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
Under the agreement, the companies plan to develop a customized solution that can be widely deployed for DNA sequencing.
The UK-based noninvasive prenatal testing firm also said that it has raised £2.5 million in funding through a share subscription.
The company is now seeking commercial partners in Brazil to make the Iona test available in the country.
Premaitha had been sued by Illumina for allegedly infringing on five patents related to noninvasive prenatal testing with its Iona test.
Premaitha entered into a secured loan facility agreement with Thermo Fisher, which is secured on the shares of Premaitha's Taiwanese subsidiary, Yourgene Bioscience.
Illumina had filed a series of suits against several companies in the UK starting in 2015, which were recently consolidated into one case.
Ampath will be one of the first laboratories in South Africa to offer a CE-IVD accredited noninvasive prenatal testing center and will act as a hub for such services.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.